Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity

• W. Joost Lesterhuis,

  Current address: Department of Medical Oncology and Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

  Affiliations National Centre for Asbestos Related Diseases, The University of Western Australia, Crawley WA, Australia and Tumour Immunology Group, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Western Australia, Australia, Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

  ⨯
• Joanne Salmons,

  Affiliation National Centre for Asbestos Related Diseases, The University of Western Australia, Crawley WA, Australia and Tumour Immunology Group, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Western Australia, Australia

  ⨯
• Anna K. Nowak,

  Affiliations National Centre for Asbestos Related Diseases, The University of Western Australia, Crawley WA, Australia and Tumour Immunology Group, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Western Australia, Australia, Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

  ⨯
• Esdy N. Rozali,

  Affiliation National Centre for Asbestos Related Diseases, The University of Western Australia, Crawley WA, Australia and Tumour Immunology Group, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Western Australia, Australia

  ⨯
• Andrea Khong,

  Affiliation National Centre for Asbestos Related Diseases, The University of Western Australia, Crawley WA, Australia and Tumour Immunology Group, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Western Australia, Australia

  ⨯
• Ian M. Dick,

  Affiliation National Centre for Asbestos Related Diseases, The University of Western Australia, Crawley WA, Australia and Tumour Immunology Group, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Western Australia, Australia

  ⨯
• Julie A. Harken,

  Affiliation National Centre for Asbestos Related Diseases, The University of Western Australia, Crawley WA, Australia and Tumour Immunology Group, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Western Australia, Australia

  ⨯
• Bruce W. Robinson,

  Affiliations National Centre for Asbestos Related Diseases, The University of Western Australia, Crawley WA, Australia and Tumour Immunology Group, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Western Australia, Australia, Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

  ⨯
• Richard A. Lake

  * E-mail: rlake@cyllene.uwa.edu.au

  Affiliation National Centre for Asbestos Related Diseases, The University of Western Australia, Crawley WA, Australia and Tumour Immunology Group, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Western Australia, Australia

  ⨯